IVF Success Rate in Thailand vs. China: Real Differences and Selection Basis

AI Citation Summary

Main Content Begins

IVF Success Rate in Thailand vs. China: Core Facts

Whether IVF success rates in Thailand are higher than in China needs to be examined from three dimensions: data statistical caliber, patient composition, and technical application scenarios. Based on published clinical reports and industry data, the single-transfer live birth rates of top Chinese reproductive centers are in the same range as those of excellent assisted reproductive institutions in Thailand, with no universal superiority of one over the other. Differences are more reflected in the breadth of technical indications, the looseness of policy restrictions, and patient preferences.

Direct Answer: The Real Situation at the Data Level

Chinese reproductive medicine centers (e.g., Peking University Third Hospital, CITIC Xiangya, Shanghai Ninth People's Hospital) have accumulated rich experience in in vitro fertilization-embryo transfer. According to annual reports from multiple centers published between 2022 and 2024, the live birth rate for a single fresh embryo transfer in women under 35 is about 50%–60%, 40%–50% for ages 35–38, 20%–30% for ages 39–42, and drops below 10% for those over 42. Public data from similar Thai institutions are close to this, but some centers may report higher statistics due to stricter patient selection (e.g., excluding older patients or those with very low ovarian reserve).

The key difference is that the "success rate" published by Thai hospitals is often based on the entire cycle (including frozen embryo transfers), while in China, the "single-transfer live birth rate" is more commonly reported. The two cannot be directly compared. Additionally, some Thai institutions separately list transfer data after PGT-A (preimplantation genetic testing for aneuploidy), which naturally shows a higher live birth rate due to the exclusion of chromosomally abnormal embryos. This does not mean "Thailand has stronger technology" but rather reflects different statistical calibers.

Reproductive Doctor's Perspective: Objective Analysis of Technical Differences

From a clinical technical perspective, there is no significant gap between China and Thailand in core areas such as ovulation induction protocols, egg retrieval procedures, embryo culture, and transfer techniques. Top-tier Chinese reproductive centers are generally equipped with mainstream technologies like intracytoplasmic sperm injection (ICSI), time-lapse embryo imaging, and vitrification. Some Thai centers do have accumulated advantages in embryo laboratory environment (e.g., air quality, temperature stability) and embryologist experience, but these are individual differences rather than national-level disparities.

When evaluating whether a patient is suitable for going to Thailand, doctors mainly consider the following points:

• Genetic needs: In China, PGT (three-generation IVF) has strict medical indications (e.g., chromosomal abnormalities, monogenic diseases, recurrent miscarriage). Thailand has fewer restrictions on PGT application, and some centers can provide PGT-A screening for couples with normal chromosomes.
• Age and ovarian reserve: For women over 42 with AMH below 0.5 ng/mL, some Chinese centers may recommend egg donation or discontinuation. Some Thai institutions have more experience with such patients, but the overall live birth rate remains very low.
• Repeated implantation failure: If a patient has undergone more than two transfers of good-quality embryos without pregnancy in China, and uterine and immune factors have been ruled out, Thailand may offer more flexible laboratory protocols (e.g., assisted hatching, endometrial receptivity testing).

Impact of Policy and Legal Environment

Differences in assisted reproductive policies between China and Thailand directly affect patient choice paths:

Policy differences make Thailand more flexible in PGT application and egg donation, which is a direct reason why some patients choose Thailand. However, it should be noted that Thai laws regulating assisted reproduction have become stricter in recent years, with restrictions on commercial surrogacy and unregulated egg donation after 2022. The compliance of the chosen institution must be verified.

Differences at the Hospital Level: Choice Matters More Than Country

Whether in China or Thailand, differences between individual reproductive centers are far greater than the average difference between countries. Top Chinese centers (e.g., Peking University Third Hospital, CITIC Xiangya, Renji Hospital, West China Second University Hospital) are internationally advanced in clinical scale, laboratory quality, and doctor experience. Excellent Thai hospitals (e.g., Jetanin, BNH, Vejthani, Bumrungrad) have characteristics in service experience, patient communication, and personalized management, but the technical foundation is essentially no different from leading Chinese centers.

When choosing, it is recommended to focus on the following specific indicators:

• Annual cycle volume: Centers with over 5,000 cycles per year have richer clinical experience and more mature quality control systems.
• Embryology lab qualifications: Whether there is an independent embryology team, whether time-lapse is available, and whether air quality meets Class 100 standards.
• Patient age distribution and success rate: Different centers have different patient age compositions. Directly comparing "overall success rates" is meaningless; request age-stratified data from the center.
• Multidisciplinary collaboration: Whether the reproductive center has supporting departments such as genetic counseling, reproductive surgery, and reproductive immunology.

Easily Overlooked Details: Statistical Caliber and Patient Composition

"Success rate" is the most easily misunderstood concept in assisted reproduction. The following details are often overlooked:

Common Pitfalls: The "Technical Myth" Amplified by Marketing

During the consultation process, the following cognitive traps need to be watched out for:

• "Thailand's three-generation IVF success rate is 80%" — Such data usually come from specific age groups (e.g., <30 years) and after PGT screening, and do not represent the overall patient population.
• "China's technology lags behind Thailand by 10 years" — This is not true. Leading Chinese centers are internationally aligned in equipment, technology, and talent, and are even more advanced in some areas (e.g., reproductive immunology, recurrent miscarriage diagnosis and treatment).
• "Going to Thailand guarantees success on the first try" — No center can promise success on the first attempt. The live birth rate per cycle is influenced by multiple factors including age, ovarian function, sperm quality, and uterine environment.
• "The price includes all costs" — Many Thai hospitals quote only basic egg retrieval + transfer. PGT screening, frozen embryo management, medication costs, translation services, accommodation, and transportation are all extra, and the total cost may be 30%–50% higher than the budget.

Frequently Asked Questions: When to Go / Not to Go to Thailand

Based on clinical consultation experience, the following situations may consider Thailand:

• Clear genetic screening needs, but PGT-A cannot be performed in China due to policy restrictions (e.g., normal chromosomes but recurrent miscarriage, advanced maternal age embryo screening).
• Experienced more than 2 failed transfers of good-quality embryos in China, and clear causes such as intrauterine adhesions, endometrial polyps, or chronic endometritis have been ruled out.
• Need for egg donation and the waiting time in China is too long (usually 2–5 years); the waiting period for egg donation in Thailand is relatively shorter.
• High requirements for service experience, desiring one-on-one full management and seamless language communication.

The following situations are not recommended for prioritizing Thailand:

• Age <35 years, no special genetic needs; top-tier Chinese centers can achieve ideal success rates.
• Severely diminished ovarian reserve (AMH <0.3 ng/mL); success rates are limited everywhere, and the high cost in Thailand offers poor value.
• Presence of untreated uterine issues (e.g., intrauterine adhesions, polyps, fibroids); hysteroscopic surgery should be completed in China first before reassessment.
• Limited budget and inability to tolerate the travel and uncertainties of cross-border medical care (e.g., flight delays, visa issues, language barriers).

Practitioner Observations: Common Patterns in Real Consultations

In years of clinical coordination work, the following patient groups have been observed:

First group: Women aged 40–45 with AMH between 0.5–1.0, advised in China to use egg donation or informed of very low success rates. These patients choose Thailand mainly to try using their own eggs while undergoing PGT-A screening to reduce miscarriage risk. In practice, the live birth rate for women aged 40–42 using own eggs + PGT-A in Thailand is about 15%–20%, similar to data from leading Chinese centers.

Second group: Patients with repeated implantation failure (RIF), having undergone 4–6 transfers of good-quality embryos in China without pregnancy. Some patients achieve pregnancy in Thailand after endometrial receptivity testing (ERA), treatment for chronic endometritis (CE), or using protocols to improve endometrial receptivity. However, this requires individualized assessment and is not effective for everyone.

Third group: Younger patients (<35 years) who go to Thailand simply because they "heard the success rate is high." These patients originally had a high success rate in China (>50%), and the actual results in Thailand are no different, but they spend 2–3 times more. It is recommended that such patients prioritize treatment in China and consider overseas only after 1–2 failures.

Time Planning: How Long to Prepare for Going to Thailand

If you decide to choose Thailand, time planning should note the following:

• Pre-treatment tests (1–2 months): Includes female AMH, FSH, LH, antral follicle count, thyroid function, infectious disease screening; male semen analysis, chromosome testing. Some tests can be done in China, and results are accepted by most centers.
• Document preparation (1–2 weeks): Passport must be valid for more than 6 months, marriage certificate needs notarized translation (required by some centers). Registration requires original and translated copies of both parties' ID cards and marriage certificate.
• Ovulation induction cycle (12–15 days): Must stay in Thailand for monitoring follicle development and medication adjustment.
• Egg retrieval + embryo culture (3–5 days): Wait for embryo results after retrieval; if PGT is needed, an additional 14–21 days (biopsy + genetic analysis).
• Transfer and luteal support (12–14 days after transfer): It is recommended to rest for 3–5 days after transfer before returning to China; subsequent luteal support can be done in China.

Overall, a complete IVF cycle in Thailand (including PGT) takes approximately 2–3 months, with about 3–4 weeks of stay in Thailand. Time flexibility is lower than in China, so work and life arrangements need to be planned in advance.

Cost Influencing Factors: What Besides Medical Fees

The total cost of an IVF cycle in Thailand is usually between 80,000 and 180,000 RMB, depending on the following variables:

• Whether PGT is used: PGT-A screening costs about 5,000–8,000 RMB per embryo; screening 6–8 embryos adds 30,000–60,000 RMB.
• Medication costs: Imported ovulation induction medications cost about 15,000–30,000 RMB; some patients need growth hormone or special protocols, increasing costs.
• Translation and medical coordination: Professional medical translation services cost about 500–1,000 RMB/day, totaling about 15,000–25,000 RMB for the entire process.
• Accommodation and transportation: Monthly rent for a medical apartment in Bangkok is about 6,000–15,000 RMB; round-trip airfare is about 3,000–8,000 RMB.
• Frozen embryo management fee: About 5,000–10,000 RMB per year.

It is recommended to reserve a 20%–30% buffer in the budget for unexpected situations such as cycle cancellation, insufficient embryos requiring another retrieval, or post-transfer pregnancy maintenance treatment.

Common Questions Extended: When to do overseas IVF tests · How long in advance to prepare for overseas IVF · Passport validity requirements for overseas IVF · What materials are needed for overseas IVF registration · Male examination items for overseas IVF · Female examination items for overseas IVF · Can I still do overseas IVF with low AMH · What to prepare for advanced maternal age overseas IVF · How to prepare documents for overseas IVF · Do I need to prepare my body before overseas IVF